HCV and host lipids: An intimate connection

Seminars in Liver Disease

Volumn 33, Issue 4, 2013, Pages 358-368

  Schaefer, Esperance A K ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

hepatitis C; host factors; hypocholesterolemia; lipid metabolism; lipoviral particle

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; CD81 ANTIGEN; CLAUDIN 1; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; FAT DROPLET; FATTY ACID SYNTHASE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE GLYCOSAMINOGLYCAN; HOST FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LIPOPROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; NIEMANN PICK C1 LIKE 1 RECEPTOR; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; OCCLUDIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; RNA DIRECTED RNA POLYMERASE; SCAVENGER RECEPTOR BI; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS PROTEIN; VIRUS RECEPTOR;

ARTICLE; AUTOPHAGY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; ENDOPLASMIC RETICULUM; FATTY ACID SYNTHESIS; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOCHOLESTEROLEMIA; LIFE CYCLE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; CHOLESTEROL; FATTY ACIDS; FATTY LIVER; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIPID METABOLISM; LIPOPROTEINS, VLDL; LIVER; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84887602906     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1358524     Document Type: Article

References (106)

1. Zaltron S., Spinetti A., Biasi L., Baiguera C., Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis: 2012; 12 02 S2
2. Merion R. M. Current status and future of liver transplantation. Semin Liver Dis: 2010; 30 4 411 421
3. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science: 1989; 244 4902 359 362
4. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med: 2005; 11 7 791 796
5. Lindenbach B. D., Meuleman P., Ploss A., et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A: 2006; 103 10 3805 3809
6. Dienes H. P., Popper H., Arnold W., Lobeck H. Histologic observations in human hepatitis non-A, non-B. Hepatology: 1982; 2 5 562 571
7. Goodman Z. D., Ishak K. G. Histopathology of hepatitis C virus infection. Semin Liver Dis: 1995; 15 1 70 81
8. Hourigan L. F., Macdonald G. A., Purdie D., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology: 1999; 29 4 1215 1219
9. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol: 2000; 33 1 106 115
10. Abid K., Pazienza V., de Gottardi A., et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol: 2005; 42 5 744 751
11. Siagris D., Christofidou M., Theocharis G. J., et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat: 2006; 13 1 56 61
12. Petit J. M., Benichou M., Duvillard L., et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol: 2003; 98 5 1150 1154
13. Lambert J. E., Bain V. G., Ryan E. A., Thomson A. B., Clandinin M. T. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology: 2013; 57 5 1697 1704
14. Clark P. J., Thompson A. J., Vock D. M., et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology: 2012; 56 1 49 56
15. Corey K. E., Kane E., Munroe C., Barlow L. L., Zheng H., Chung R. T. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology: 2009; 50 4 1030 1037
16. Hui J. M., Kench J., Farrell G. C., et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol: 2002; 17 8 873 881
17. Corey K. E., Mendez-Navarro J., Barlow L. L., et al. Acute hepatitis C infection lowers serum lipid levels. J Viral Hepat: 2011; 18 7 e366 e371
18. Butt A. A., Xiaoqiang W., Budoff M., Leaf D., Kuller L. H., Justice A. C. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis: 2009; 49 2 225 232
19. Petta S., Torres D., Fazio G., et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology: 2012; 55 5 1317 1323
20. Mason A. L., Lau J. Y., Hoang N., et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology: 1999; 29 2 328 333
21. Mostafa A., Mohamed M. K., Saeed M., et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut: 2010; 59 8 1135 1140
22. Bridge S. H., Sheridan D. A., Felmlee D. J., et al. Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. Gut: 2011; 60 5 680 687
23. Sheridan D. A., Price D. A., Schmid M. L., et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther: 2009; 29 12 1282 1290
24. Harrison S. A., Rossaro L., Hu K. Q., et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology: 2010; 52 3 864 874
25. Clark P. J., Thompson A. J., Zhu M., et al. IDEAL investigators Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat: 2012; 19 5 332 340
26. Thomssen R., Bonk S., Propfe C., Heermann K. H., Köchel H. G., Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl): 1992; 181 5 293 300
27. Nielsen S. U., Bassendine M. F., Burt A. D., Martin C., Pumeechockchai W., Toms G. L. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol: 2006; 80 5 2418 2428
28. André P., Komurian-Pradel F., Deforges S., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol: 2002; 76 14 6919 6928
29. Gastaminza P., Dryden K. A., Boyd B., et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol: 2010; 84 21 10999 11009
30. Scholtes C., Ramière C., Rainteau D., et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology: 2012; 56 1 39 48
31. Merz A., Long G., Hiet M. S., et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem: 2011; 286 4 3018 3032
32. Catanese M. T., Uryu K., Kopp M., et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A: 2013; 110 23 9505 9510
33. Dao Thi V. L., Granier C., Zeisel M. B., et al. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem: 2012; 287 37 31242 31257
34. Ploss A., Evans M. J. Hepatitis C virus host cell entry. Curr Opin Virol: 2012; 2 1 14 19
35. Ploss A., Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut: 2012; 61 S1 i25 35
36. Jiang J., Cun W., Wu X., Shi Q., Tang H., Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol: 2012; 86 13 7256 7267
37. Acton S., Rigotti A., Landschulz K. T., Xu S., Hobbs H. H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science: 1996; 271 5248 518 520
38. Covey S. D., Krieger M., Wang W., Penman M., Trigatti B. L. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol: 2003; 23 9 1589 1594
39. von Hahn T., Lindenbach B. D., Boullier A., et al. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology: 2006; 43 5 932 942
40. Zahid M. N., Turek M., Xiao F., et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology: 2013; 57 2 492 504
41. Catanese M. T., Ansuini H., Graziani R., et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol: 2010; 84 1 34 43
42. Dorner M., Horwitz J. A., Donovan B. M., et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature: 2013; 501 7466 237 241
43. Catanese M. T., Loureiro J., Jones C. T., Dorner M., von Hahn T., Rice C. M. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol: 2013; 87 15 8282 8293
44. Syder A. J., Lee H., Zeisel M. B., et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol: 2011; 54 1 48 55
45. Lacek K., Vercauteren K., Grzyb K., et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol: 2012; 57 1 17 23
46. Zeisel M. B., Koutsoudakis G., Schnober E. K., et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology: 2007; 46 6 1722 1731
47. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science: 1998; 282 5390 938 941
48. Kapadia S. B., Chisari F. V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A: 2005; 102 7 2561 2566
49. Owen D. M., Huang H., Ye J., Gale M. Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology: 2009; 394 1 99 108
50. Mazumdar B., Banerjee A., Meyer K., Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology: 2011; 54 4 1149 1156
51. Albecka A., Belouzard S., Op de Beeck A., et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology: 2012; 55 4 998 1007
52. Sainz B. Jr, Barretto N., Martin D. N., et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med: 2012; 18 2 281 285
53. Su A. I., Pezacki J. P., Wodicka L., et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A: 2002; 99 24 15669 15674
54. Fujino T., Nakamuta M., Yada R., et al. Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver. Hepatol Res: 2010; 40 9 923 929
55. Brown M. S., Goldstein J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell: 1997; 89 3 331 340
56. Jeon T. I., Osborne T. F. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab: 2012; 23 2 65 72
57. Waris G., Felmlee D. J., Negro F., Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol: 2007; 81 15 8122 8130
58. Park C. Y., Jun H. J., Wakita T., Cheong J. H., Hwang S. B. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem: 2009; 284 14 9237 9246
59. Kim K. H., Hong S. P., Kim K., Park M. J., Kim K. J., Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun: 2007; 355 4 883 888
60. García-Mediavilla M. V., Pisonero-Vaquero S., Lima-Cabello E., et al. Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Invest: 2012; 92 8 1191 1202
61. Oem J. K., Jackel-Cram C., Li Y. P., et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol: 2008; 89 Pt 5 1225 1230
62. Jackel-Cram C., Babiuk L. A., Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol: 2007; 46 6 999 1008
63. Jopling C. L., Yi M., Lancaster A. M., Lemon S. M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science: 2005; 309 5740 1577 1581
64. Jangra R. K., Yi M., Lemon S. M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol: 2010; 84 13 6615 6625
65. Lanford R. E., Hildebrandt-Eriksen E. S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science: 2010; 327 5962 198 201
66. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
67. Esau C., Davis S., Murray S. F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab: 2006; 3 2 87 98
68. Singaravelu R., Chen R., Lyn R. K., et al. Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis. Hepatology: 2013
69. Cheng Y., Dharancy S., Malapel M., Desreumaux P. Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J Gastroenterol: 2005; 11 48 7591 7596
70. Vescovo T., Romagnoli A., Perdomo A. B., et al. Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology: 2012; 142 3 644 653, e3
71. Li Q., Pène V., Krishnamurthy S., Cha H., Liang T. J. Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med: 2013; 19 6 722 729
72. Ye J., Wang C., Sumpter R. Jr, Brown M. S., Goldstein J. L., Gale M. Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A: 2003; 100 26 15865 15870
73. Kim S. S., Peng L. F., Lin W., et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology: 2007; 132 1 311 320
74. Peng L. F., Schaefer E. A., Maloof N., et al. Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. J Infect Dis: 2011; 204 4 609 616
75. Wang C., Gale M. Jr, Keller B. C., et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell: 2005; 18 4 425 434
76. Rodgers M. A., Villareal V. A., Schaefer E. A., et al. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus. J Am Chem Soc: 2012; 134 16 6896 6899
77. Yang W., Hood B. L., Chadwick S. L., et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology: 2008; 48 5 1396 1403
78. Nasheri N., Joyce M., Rouleau Y., et al. Modulation of fatty acid synthase enzyme activity and expression during hepatitis C virus replication. Chem Biol: 2013; 20 4 570 582
79. Huang J. T., Tseng C. P., Liao M. H., et al. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase. J Virol: 2013; 87 9 4994 5004
80. Tai A. W., Benita Y., Peng L. F., et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe: 2009; 5 3 298 307
81. Li Q., Brass A. L., Ng A., et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A: 2009; 106 38 16410 16415
82. Vaillancourt F. H., Pilote L., Cartier M., et al. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology: 2009; 387 1 5 10
83. Tai A. W., Salloum S. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS ONE: 2011; 6 10 e26300
84. Romero-Brey I., Merz A., Chiramel A., et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog: 2012; 8 12 e1003056
85. Miyanari Y., Atsuzawa K., Usuda N., et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol: 2007; 9 9 1089 1097
86. Lyn R. K., Kennedy D. C., Sagan S. M., et al. Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism. Virology: 2009; 394 1 130 142
87. Depla M., Uzbekov R., Hourioux C., et al. Ultrastructural and quantitative analysis of the lipid droplet clustering induced by hepatitis C virus core protein. Cell Mol Life Sci: 2010; 67 18 3151 3161
88. Shavinskaya A., Boulant S., Penin F., McLauchlan J., Bartenschlager R. The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J Biol Chem: 2007; 282 51 37158 37169
89. Roingeard P., Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat: 2008; 15 3 157 164
90. Piodi A., Chouteau P., Lerat H., Hézode C., Pawlotsky J. M. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology: 2008; 48 1 16 27
91. Counihan N. A., Rawlinson S. M., Lindenbach B. D. Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog: 2011; 7 10 e1002302
92. Herker E., Harris C., Hernandez C., et al. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med: 2010; 16 11 1295 1298
93. Tanaka T., Kuroda K., Ikeda M., Wakita T., Kato N., Makishima M. Hepatitis C virus NS4B targets lipid droplets through hydrophobic residues in the amphipathic helices. J Lipid Res: 2013; 54 4 881 892
94. Camus G., Herker E., Modi A. A., et al. Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core. J Biol Chem: 2013; 288 14 9915 9923
95. Harris C., Herker E., Farese R. V. Jr, Ott M. Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem: 2011; 286 49 42615 42625
96. Benoist F., Grand-Perret T. Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein. J Biol Chem: 1997; 272 33 20435 20442
97. Huang H., Sun F., Owen D. M., et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A: 2007; 104 14 5848 5853
98. Nahmias Y., Goldwasser J., Casali M., et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology: 2008; 47 5 1437 1445
99. Benga W. J., Krieger S. E., Dimitrova M., et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology: 2010; 51 1 43 53
100. Goldwasser J., Cohen P. Y., Lin W., et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol: 2011; 55 5 963 971
101. Jiang J., Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol: 2009; 83 24 12680 12691
102. Mirandola S., Realdon S., Iqbal J., et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology: 2006; 130 6 1661 1669
103. O'Leary J. G., Chan J. L., McMahon C. M., Chung R. T. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology: 2007; 45 4 895 898
104. Bader T., Fazili J., Madhoun M., et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol: 2008; 103 6 1383 1389
105. Bader T., Hughes L. D., Fazili J., et al. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients. J Viral Hepat: 2013; 20 9 622 627
106. Zhu Q., Li N., Han Q., et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Antiviral Res: 2013; 98 3 373 379